/SPRY

ARS Pharmaceuticals Inc

SPRY

$4.76USD↓-5.93%-0.30 today

MARKET CAP

473.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$5

$13

AI Summary

Stalk

Sell NowHigh

SPRY is in a confirmed Stage 4 decline with medium-term bearish bias reinforced by an active Support Failure pattern. Price remains below declining 9-, 21-, and 50-period EMAs, with rallies consistently rejected. No mean-reversion eligibility is present, and speculative execution favors an immediate Sell Now into resistance near the broken support cluster.

↑Q2 2026 revenue of $33.7M topped consensus by 7.5% on neffy demand
↑Neffy holds 5% US epinephrine share with 16,000 unique prescribers
↓Q2 net loss of $62.3M (-$0.63/share) missed estimates by 31%

Full analysis →

Buying

5

institutions

Selling

5

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	5.31 M	42.54 M	+299.06 K	+5.7%	0.00%
MM Millennium Management LLC Q2 2026	SELL	2.52 M	20.19 M	+-3.46 M	-58.0%	0.01%
AC Adar1 Capital Management, LLC Q2 2026	SELL	601.00 K	4.81 M	+-760.54 K	-56.0%	0.22%
CA Citadel Advisors LLC Q2 2026	SELL	566.56 K	4.54 M	+-1.27 M	-69.3%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	363.32 K	3.11 M	+-19.48 K	+4.0%	0.00%
EP Eversept Partners, LP Q2 2026	BUY	377.01 K	3.02 M	+240.77 K	+176.0%	0.16%
BA Balyasny Asset Management L.P. Q2 2026	BUY	64.66 K	517.91 K	+2.91 K	+4.5%	0.00%
JH Janus Henderson Group Plc Q1 2026	BUY	43.20 K	347.11 K	+21.60 K	+37.9%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	35.68 K	285.76 K	+9.80 K	+37.5%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-46.56 K	-100.0%	0.00%